Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress

Cancer cells produce galectin-1 as a tumor promoting protein. Thiodigalactoside (TDG) as a non-metabolised small drug, is shown to suppress tumor growth by inhibiting multiple cancer enhancing activities of galectin-1, including immune cell dysregulation, angiogenesis and protection against oxidativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Koichi, Scott, Stacy A., Cutler, Samuel, Dong, Lan-Feng, Neuzil, Jiri, Blanchard, Helen, Ralph, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155035/
https://www.ncbi.nlm.nih.gov/pubmed/21523436
http://dx.doi.org/10.1007/s10456-011-9213-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155035/
https://www.ncbi.nlm.nih.gov/pubmed/21523436
http://dx.doi.org/10.1007/s10456-011-9213-5

Ejemplares similares